SCHEDULE: Indaptus Therapeutics Sees Major Ownership Shift, New CEO

A group of investors led by Yun Yao acquired a controlling stake in Indaptus Therapeutics, leading to a significant change in beneficial ownership and the appointment of a new CEO.

Summary

• A group of six reporting persons, including Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang, and Lina Deng, acquired a substantial stake in Indaptus Therapeutics, Inc.
• The group purchased 196,800 shares of Series AA Preferred Stock and 700,000 shares of Series AAA Preferred Stock from David Elliot Lazar for an aggregate price of $11,200,000.
• These preferred shares were converted into 108,936,000 shares of common stock on March 24, 2026, following stockholder approval on February 26, 2026.
• The conversion significantly increased the total common stock outstanding from 2,242,324 shares (as of March 16, 2026) to 111,178,324 shares (as of March 30, 2026).
• The reporting group collectively beneficially owns 108,936,000 shares, representing approximately 97.98% of the total outstanding common stock.
• Individual beneficial ownership percentages are: Yun Yao (37.8%), Sino Lion Ventures Limited (35.0%), Chenhao Xu (35.0% as controlling person of Sino Lion), Junyi Dai (10.1%), Ting Yang (10.1%), and Lina Deng (5.0%).
• Junyi Dai was appointed as the new Chief Executive Officer and a member of the Board of Directors, effective March 23, 2026.
• A holdback amount of $560,000 (5% of the purchase price) is held in escrow for six months to cover potential losses from seller's breaches, undisclosed liabilities, or third-party claims.
• The transaction also required the termination of the YA II PN SEPA financing agreement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative event for existing common shareholders due to extreme dilution, despite the new investment and management. The change of control and new strategic direction introduce uncertainty.

Positives

• Significant new investment of $11.2 million into the company through the acquisition of preferred stock.
• Appointment of a new Chief Executive Officer, Junyi Dai, and a new director, which could signal a fresh strategic direction.
• The new investor group intends to actively engage with management and the Board to pursue strategic opportunities and drive value for stockholders.
• The termination of the YA II PN SEPA financing agreement could remove a potential overhang or complex financing structure.

Negatives

• The conversion of preferred stock resulted in a massive dilution of existing common stockholders, increasing outstanding shares from 2.24 million to over 111 million.
• The seller, David Elliot Lazar, an officer and director, sold 96.2% of his equity securities, indicating a near-complete exit of a significant insider.
• The escrow arrangement for potential losses from seller's breaches or undisclosed liabilities suggests a degree of caution or potential concern regarding past financial disclosures or operations.

Risks

• Significant Dilution: The conversion of preferred stock into common stock has resulted in a substantial increase in the number of outstanding common shares, which will significantly dilute the ownership percentage and potentially the value per share for existing common stockholders.
• Integration Risk: Changes in management and a new controlling shareholder group may lead to shifts in strategy, operations, and corporate culture, which could present integration challenges.
• Undisclosed Liabilities: The escrow arrangement for potential losses related to undisclosed liabilities or breaches of seller's representations and warranties highlights a risk of unforeseen financial obligations.
• Market Reaction to Dilution: The substantial increase in outstanding shares could negatively impact the stock price due to the significant dilution.
• Dependence on New Management/Shareholders: The company's future direction and success will heavily depend on the strategic decisions and execution capabilities of the new CEO and the controlling shareholder group.

Future Outlook

The reporting persons intend to continuously review their investment and may engage with the Issuer's management and Board to pursue strategic opportunities, discuss business operations, governance, strategy, capitalization, ownership, and future plans. They may also consider purchasing additional securities, selling existing holdings, or engaging in hedging transactions based on various factors including the Issuer's financial position and market conditions.

Management Comments

• Junyi Dai was appointed as the Chief Executive Officer and a member of the Board of Directors of the Issuer, effective March 23, 2026.
• Mmes. Yao and Deng and Messrs. Xu and Yang may from time to time engage with the Issuer to pursue strategic opportunities to drive value for the Stockholders.
• Mmes. Yao and Deng and Messrs. Xu and Yang intend to review their investment in the Issuer on a continuing basis and may engage in discussions with the Issuer's management, the Board, other holders of shares of Common Stock, industry analysts or existing or potential strategic partners and other third parties regarding a variety of matters relating to the Issuer.

Industry Context

StockSavvy.ai notes that this transaction represents a significant change of control for Indaptus Therapeutics, with a new investor group acquiring a dominant stake and installing new leadership. Such events often signal a strategic pivot or a recapitalization effort, particularly when accompanied by substantial dilution for existing public shareholders. The exit of a major insider (David Elliot Lazar) and the entry of a new, large investor group could indicate a shift in the company's long-term vision or a move to address underlying operational or financial challenges.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• The Securities Purchase Agreement, dated March 19, 2026, was entered into between David Elliot Lazar (Seller), an officer and director of the Issuer, and the Purchasers for the sale of Preferred Stock.

Stakeholder Impact

• Shareholders: Existing common stockholders face significant dilution due to the conversion of preferred stock, which increased outstanding shares by over 4800%. This will likely negatively impact per-share value. New shareholders (the reporting group) now hold a controlling interest, potentially leading to new strategic directions.
• Management/Employees: A new CEO has been appointed, which could lead to further changes in management or strategic priorities.
• Creditors: The termination of the YA II PN SEPA financing agreement could alter the company's debt structure or financing arrangements.
• Suppliers/Customers: No direct impact mentioned, but a change in strategic direction under new ownership could indirectly affect business relationships.

Next Steps

• The reporting persons will continue to review their investment and may engage in discussions with management and the Board regarding strategic opportunities, business, operations, governance, strategy, capitalization, ownership, and future plans.
• The reporting persons may purchase additional shares, sell existing shares, or engage in hedging transactions in the future.
• The Issuer is required to include the shares of Common Stock underlying the Series AA Preferred Stock retained by the Seller in a resale registration statement within 30 days of the Closing.
• The escrow agent will release the holdback amount to the Seller on the Holdback Release Date (six months following the filing of the Issuer's Annual Report on Form 10-K for fiscal year ended December 31, 2025), subject to any outstanding claims.

Key Dates

Recommendation

The filing reveals an extreme level of dilution for existing common shareholders, with the outstanding share count increasing by over 4800% from 2.24 million to 111.18 million shares. This massive dilution, coupled with a major insider (David Elliot Lazar) selling nearly all of his equity, signals a significant negative event for current investors. While new capital and management are introduced, the immediate and severe dilution fundamentally alters the investment thesis, making it a strong sell for existing common stockholders. The new controlling group's future actions and strategic direction are uncertain, adding further risk.

Keywords

Indaptus Therapeutics, INDP, Schedule 13D, beneficial ownership, preferred stock conversion, stock dilution, CEO appointment, corporate governance, strategic investment, Yun Yao, Sino Lion Ventures, Junyi Dai, David Elliot Lazar